These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 31156366)

  • 1. Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease.
    Li DD; Zhang YH; Zhang W; Zhao P
    Front Neurosci; 2019; 13():472. PubMed ID: 31156366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis.
    Jin BR; Liu HY
    Neural Regen Res; 2019 May; 14(5):805-816. PubMed ID: 30688266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
    Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine for vascular cognitive impairment.
    Craig D; Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD004746. PubMed ID: 16437493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis.
    Atri A; Hendrix SB; Pejović V; Hofbauer RK; Edwards J; Molinuevo JL; Graham SM
    Alzheimers Res Ther; 2015; 7(1):28. PubMed ID: 25991927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study.
    Wang J; Guo X; Lu W; Liu J; Zhang H; Quan Q; Su H; Ma L; Gao F; Qu Q
    J Alzheimers Dis; 2021; 80(2):673-681. PubMed ID: 33579850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
    Schneider LS; Dagerman KS; Higgins JP; McShane R
    Arch Neurol; 2011 Aug; 68(8):991-8. PubMed ID: 21482915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine for Alzheimer's disease.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2004 Oct; (4):CD001747. PubMed ID: 15495017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
    Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
    Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.